Transcriptional profiling on a panel of seven breast cancer cell lines showed indeed a characteristic signature of significantly downregulated genes for abemaciclib that goes beyond the profile of the target protein CDK4/6 kinase activity46. This evidence concerns the gene CDK4 and breast cancer.